Background and Purpose-The intensity of the inflammatory response may be related to the volume of acute infarction.
xperimental data have shown that focal cerebral ischemia induces a time-dependent activation of granulocytes, lymphocytes, and macrophages. Macrophage activity through the early activation of resident microglia and the infiltration of hematogenous monocytes starts after a delay of 1 to 5 days and persists for a longer time period. 1 A relationship between the volume of brain tissue damage and the inflammatory process has been demonstrated in experimental models and clinical studies. 2, 3 In addition to positron emission tomography methods using the ligand [ 11 C] (R)-PK11195, 4 ultra-small superparamagnetic particles of iron oxide (USPIO) may also assess neuroinflammation. USPIO remain for several days in the lysosomes of macrophages, where they induce a signal increase in T1 and a signal decrease in T2*-weighted images. [5] [6] [7] MRI data evaluating neuroinflammation in stroke patients are scarce. 5 Our aim was to assess the relationship between the subacute ischemic lesion volume and the intensity of the inflammatory response.
Methods

Patients
We enrolled patients in this study who presented with documented acute anterior circulation stroke, with a National Institutes of Health Stroke Scale (NIHSS) score Ն8, and who were not eligible for thrombolytic therapy. Oral and written informed consent was obtained before inclusion. Major exclusion criteria were: (1) brain hematoma on initial brain CT scan or MRI; (2) initial MRI performed Ͼ24 hours previously; (3) ambiguous time of symptom onset; (4) lesion size below 1 cm 3 on diffusion-weighted imaging on initial stroke imaging; (5) enrolment into other clinical studies; (6) past history of neoplasia or known active liver disease; (7) administration of gadolinium complexes within 24 hours or iron particles within 6 months before this study; (8) known allergy to dextran or drugs containing iron salts; and (9) current contraindications to MRI.
The study design was approved by our ethical committee (CCPPRB Lyon B).
MRI Protocol
A sequential MRI approach was designed. MRI was performed at day 0, day 6, and day 9 on a 1.5-T clinical magnet (Philips Intera). The MRI protocol included gradient-echo T2*-weighted imaging (T2*WI), diffusion-weighted imaging (DWI), perfusion-weighted imaging, fluid-attenuated inversion recovery, T1-weighted imaging (T1WI), and 3-dimensional time-of-flight angiography, with the following parameters: USPIO (ferumoxtran, AMI-227, Sinerem) were kindly provided by Guerbet (Roissy CDG Cedex, France) and reconstituted according to the manufacturer's instructions. It was administered in a single dose infusion (2.6 mg iron/kg body weight) through a 0.22-m pore filter at a rate of 4 mL/min immediately after the day 6 MRI. A close monitoring of adverse events related to Sinerem infusion was performed.
Image Analysis
Image analysis was performed by consensus by 2 senior neuroradiologists (M.H., Y.B.). Infarct volume was assessed by manual contouring of signal abnormalities on day 6 DWI obtained at bϭ1000 s/mm 2 . Lesion volume was determined by multiplying the area of diffusion hyperintensity by the sum of the slice thickness and the interslice gap. Volume of signal changes attributed to USPIO were assessed both on T1WI and T2*WI at day 9. Volumes of USPIO-related signals were delineated manually, by the consensus of 2 neuroradiologists, in cerebral parenchyma, excluding large vessels. Because the analysis of USPIO-related signal changes could be affected by hemorrhagic transformation of brain infarction, the volume of hemorrhagic transformation-related signal changes was assessed at day 6 T1WI or T2*WI, and was removed from the day 9 USPIO signal change volume. Blood-brain barrier (BBB) disruption was assessed at day 6 before USPIO administration on T1-weighted sequence. BBB disruption imaging was obtained using Gd-DTPA at 0.1 mmol/kg. BBB disruption was classified as absent, mild (Ͻ1/3 of the middle cerebral artery [MCA] territory), or severe (Ͼ1/3 of the MCA territory). USPIO enhancement ratios were defined as the ratio between USPIO-related signal volume on day 9 T1WI (respectively T2*WI) and day 6 DWI infarct volume.
Statistical Analysis
The descriptive statistics of the NIHSS score and MRI characteristics are given as mean values with standard deviation or median values and range. Two-tailed paired Student t test was used to compare DWI lesion volume at day 6 and day 9. Pearson and Spearman correlation tests were used to assess the relationship between the volume of the lesion at day 6 and USPIO enhancement ratio at day 9. Probability values of 0.05 or less were considered to indicate statistical significance. Statistical analysis was performed with the SPSS 11 (SPSS Science) statistical software package for Windows.
Results
Eleven consecutive patients ( Ischemic strokes were localized to the MCA territory (superficial MCA territory, nϭ6; the lenticulostriate territory, nϭ3; the entire MCA territory, nϭ1). An arterial occlusion was observed at baseline magnetic resonance angiography in 7 patients, involving the proximal MCA (nϭ3) and the MCA insular branches (nϭ4). A spontaneous recanalization was observed in 6/7 patients on day 6 magnetic resonance angiography. At day 6, we did not observe a significant perfusion defect between the 2 hemispheres with regard to time-to-peak maps. A mild BBB disruption was observed in 6 cases, and a marked BBB disruption in 1 case (Table) . There was no relation between BBB disruption and USPIOrelated signal changes.
Median lesion volume was 59.5 cm 3 on day 6 DWI (range, 2 to 240 cm 3 ) and 39.5 cm 3 on day 9 DWI (range, 2 to 210 cm 3 ). The difference in lesion volume between day 6 and day 9 was not significant (Pϭ0.59). Median USPIO-enhanced volume on day 9 T1WI was 2.5 cm 3 (range, 0 to 42 cm 3 ). Median USPIO-signal loss volume on day 9 T2*WI was 0.5 cm 3 (range, 0 to 9 cm 3 ). USPIO signal alterations are illustrated in 3 cases in Figure 1 . Enhancement after USPIO injection was observed in 9/10 patients on day 9 T1WI and in 5/10 patients on day 9 T2*WI. T1WI and T2*WI USPIO signal alterations were confined within the ischemic area assessed at day 6 DWI. We did not observe any USPIO enhancement remote from the day 6 DWI ischemic area. A heterogeneous distribution of ratios was found (Figure 2) . Values for the T1 enhancement ratio (USPIO enhanced volume on day 9 T1WI/d 6 DWI lesion volume) ranged from 0 to 0.93 (median, 0.07). Values for the T2* ratio (USPIOenhanced volume at day 9 T2*WI/d 6 DWI lesion volume) ranged from 0 to 0.20 (median, 0.02). The day 6 DWI lesion volume had no impact on USPIO enhancement at day 9: there was no statistically significant relationship, according to the Pearson correlation test (Pϭ0.39) or Spearman test (Pϭ0.25; Figure 2 ). No adverse effects were observed after USPIO infusion.
Discussion
To date, many systemic biomarkers of inflammation involved in ischemic injury have been identified. 8 The systemic inflammatory response after stroke likely results from a response to the necrotic tissue itself. Audebert et al 9 have shown that an increase in inflammatory parameters correlates significantly with lesion volume and stroke severity. Necrotic tissue is eliminated by cellular, humoral, or metabolic mechanisms, which are all part of the inflammatory reaction. 10 The dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction, and their correlation with the volume of brain tissue damage, have been demonstrated using technetium-99m hexamamethylpropyleneamine oxime (99m Tc HMPAO)-labeled leukocyte brain single-photon emission computed tomography (SPECT) in a previous clinical study. 4 Therefore, we speculated that postischemic neuroinflammation as demonstrated by USPIO enhancement may be correlated with subacute volume assessed with DWI. In our study, the presence or absence of USPIO enhancement could not be predicted by known clinical or MRI parameters. Indeed, USPIO enhancement was heterogeneous, and the overall volumes of USPIO signal alterations were smaller than the ischemic lesion volumes.
USPIOs have recently been introduced as a cell-specific MRI contrast agent taken up by macrophages. 11 The proof of concept that USPIO can visualize macrophage infiltrations has been confirmed in animals and patients in several applications (carotid atherosclerotic lesions, stroke, brain tumors and multiple sclerosis). 12 The USPIO signal alterations observed in ischemic areas of stroke patients is probably related to the visualization of inflammatory macrophage recruitment because animal experiments in such models showed close matching of USPIO-induced signal alterations with the distribution of iron-laden macrophages on histological brain sections. 6, 7, [13] [14] [15] We designed our protocol according to literature data. The time window used for acute and pre-and post-USPIOs imaging was derived from a study investigating the inflammatory response in stroke patients that had died 15 hours to 18 days postinjury, showing that macrophages accumulated in the infarcts at 5Ϯ9 days, 16 and from the single available clinical data, 5 in which the potential of USPIO-enhanced MRI was demonstrated in human stroke by infusing USPIO at day 6 postinjury and imaging patients twice between 24 and 72 hours post-USPIO administration. In this study, T1 effects were maximal on the second scan (48 to 72 hours). Therefore, in the present study patients were imaged at day 6 before USPIO administration and at day 9, ie, 72 hour postinjection. We found that parenchymal enhancement was more extended on T1WI compared with T2*WI, in agreement with the latter report. 5 The main difficulty in validating the USPIO-enhanced MRI technique as a marker of neuroinflammation is to rule out the possibility of nonspecific USPIO brain uptake: for instance, passive leakage through a damaged BBB. However, USPIOrelated signal alterations differed from gadolinium-enhanced regions. Moreover, 3 patients had USPIO enhancement on T1WI without BBB disruption, whereas the patient with severe BBB disruption did not show any USPIO-related enhancement. The signal alterations observed in the parenchyma must therefore be assigned to an active mechanism, most likely macrophage uptake.
There are several limitations in our study: (1) the small sample size; (2) USPIO are selectively captured by macrophagic cells 12 ; this contrast agent may thus underestimate the intensity of the inflammatory response, because the dynamic of the postischemic neuroinflammation process involves several cell types, including granulocytes and T lymphocytes; (3) differing degrees and timing of reperfusion may influence the results. However, magnetic resonance angiography showed a spontaneous recanalization before USPIO injection in 6 of 7 patients in whom an arterial occlusion was found, and we did not find any significant perfusion defect between both hemisphere.
In summary, this study confirms that brain inflammation after stroke is a heterogenous process. 5 Though further investigation involving larger groups of patients is warranted, USPIO-enhanced MRI appears as a promising technique to (1) Day 6 DWI: left superficial MCA territory stroke; (2) Cortical enhancement (arrow), consistent with BBB disruption, was observed on day 6 T1WI after intravenous gadolinium injection; (3, 4) No signal change related to USPIO was present on day-9 T2*WI 3 and on day-9 T1WI. 4 provide new in vivo information about neuroinflammation in human stroke. 
